1. Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
   Xuzhi He et al, 2018, Oncotarget CrossRef
2. Monoclonal Antibodies in Oncology: A Decade of Novel Options
   Vaibhavi Kardile et al, 2023, Cell Biochemistry and Biophysics CrossRef
3. Contribution of natural killer cells in innate immunity against colorectal cancer
   Zeinab Ghazvinian et al, 2023, Frontiers in Oncology CrossRef
4. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
   Nina Mallmann-Gottschalk et al, 2019, International Journal of Molecular Sciences CrossRef
5. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
   Myeong Geun Choi et al, 2024, Journal for ImmunoTherapy of Cancer CrossRef
6. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
   Kyusang Hwang et al, 2021, Biomedicines CrossRef
7. Innate tumor killers in colorectal cancer
   Fengyun Zhong et al, 2022, Cancer Letters CrossRef
8. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
   Ensaf M. Al-Hujaily et al, 2022, International Journal of Molecular Sciences CrossRef
9. The role of natural killer cell in gastrointestinal cancer: killer or helper
   Feixue Wang et al, 2021, Oncogene CrossRef
10. Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1
    Daniel Plano et al, 2017, Expert Opinion on Therapeutic Patents CrossRef
11. Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects
    Chenfei Zhou et al, 2019, Frontiers of Medicine CrossRef
12. Therapeutic approaches to enhance natural killer cell cytotoxicity
    Terran D. Stenger et al, 2024, Frontiers in Immunology CrossRef
13. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
    Cristina Aparicio et al, 2021, International Journal of Molecular Sciences CrossRef
14. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)
    Feng Xiong et al, 2023, Expert Review of Gastroenterology & Hepatology CrossRef
15. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
    Nico B. Volz et al, 2020, Cancers CrossRef
16. Combinatorial Immunotherapies for Metastatic Colorectal Cancer
    Eline Janssen et al, 2020, Cancers CrossRef
17. Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system
    Saeed Sadeghi et al, 2023, NK Cells in Cancer Immunotherapy: Successes and Challenges CrossRef
18. APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
    Ramya Thota et al, 2021, Cancers CrossRef
19. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
    Robert L. Ferris et al, 2018, Cancer Treatment Reviews CrossRef
20. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
    Jesús García-Foncillas et al, 2019, Frontiers in Oncology CrossRef
21. Perspectives on Immunotherapy of Metastatic Colorectal Cancer
    Yongjiu Dai et al, 2021, Frontiers in Oncology CrossRef